AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22817667 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib followed by chemotherapy after progression
Number of subjects: 0
Study 22817667 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy followed by erlotinib after progression
Number of subjects: 0
Study 19454124 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal micronutrient supplementation
Number of subjects: 4096
Study 17392439 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of the rrgC gene in vaccine-type strains
Number of subjects: 100
Study 17392439 — intervention group
Group type: COMPARATOR
Intervention: Frequency of rrgC in isolates before and after 2000
Number of subjects: 100
Study 17392439 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance of multilocus sequence types with rrgC presence
Number of subjects: 100
Study 16305317 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiplash patients (WAD)
Number of subjects: 92
Study 16305317 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiplash patients with head/neck turned at collision
Number of subjects: 92
Study 16305317 — intervention group
Group type: EXPERIMENTAL
Intervention: Front collisions
Number of subjects: 92
Study 16305317 — intervention group
Group type: COMPARATOR
Intervention: Control persons
Number of subjects: 92
Study 11895146 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with fish oil (0.2 g/kg body weight per day) plus soybean oil (1.0 g/kg per day)
Number of subjects: 60
Study 11895146 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (1.2 g/kg per day)
Number of subjects: 60
Study 11895146 — intervention group
Group type: COMPARATOR
Intervention: Fat-free regimen
Number of subjects: 60
Study 9751068 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg salbutamol via diskhalers
Number of subjects: 12
Study 9751068 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg salbutamol via diskhalers
Number of subjects: 12
Study 9751068 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg salbutamol via metered-dose inhalers (MDIs)
Number of subjects: 12
Study 9751068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7917690 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion
Number of subjects: 63
Study 3289831 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg lormetazepam
Number of subjects: 145
Study 3289831 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg lormetazepam
Number of subjects: 145
Study 29624601 — intervention group
Group type: EXPERIMENTAL
Intervention: AP scan® measurements
Number of subjects: 41
Study 27152103 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute oral administration of 250 mL of mangosteen-based juice (305 mg of α-mangostin and 278 mg of hydroxycitric acid)
Number of subjects: 12
Study 27152103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control treatment)
Number of subjects: 12
Study 25621927 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy (MDFT)
Number of subjects: 112
Study 25621927 — intervention group
Group type: COMPARATOR
Intervention: Group therapy (AGT)
Number of subjects: 112
Study 25621927 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (MDFT and AGT)
Number of subjects: 112
Study 23240743 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 100
Study 23240743 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 100
Study 21676054 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care (brochure, motivational interview, nicotine patches, phone call at 3 days)
Number of subjects: 338
Study 21676054 — intervention group
Group type: COMPARATOR
Intervention: Usual care (smoking cessation brochure)
Number of subjects: 338
Study 21676054 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care
Number of subjects: 338
Study 21676054 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 338
Study 18652324 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of botulinum toxin type A (BTX‐A) into tender points at the third lumbar transverse process or surrounding acupoints.
Number of subjects: 25
Study 18652324 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at the same points as in the acupoint-injection group.
Number of subjects: 25
Study 17035442 — intervention group
Group type: EXPERIMENTAL
Intervention: Rollator use
Number of subjects: 31
Study 12932433 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 0
Study 12932433 — intervention group
Group type: COMPARATOR
Intervention: Placebo (27.3 mg saccharin)
Number of subjects: 0
Study 10789026 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Number of subjects: 0
Study 10789026 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy
Number of subjects: 0
Study 9097873 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐CPP (0.5 mg/kg of body weight)
Number of subjects: 31
Study 9097873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8040669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IL-2 (720,000 IU/kg)
Number of subjects: 125
Study 8040669 — intervention group
Group type: COMPARATOR
Intervention: Low-dose IL-2 (72,000 IU/kg)
Number of subjects: 125
Study 2923686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin sodium
Number of subjects: 20
Study 2923686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 4880407 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron preparation 1
Number of subjects: 30
Study 4880407 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron preparation 2
Number of subjects: 30
Study 4880407 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 30
Study 31744312 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study 31744312 — intervention group
Group type: COMPARATOR
Intervention: Usual care sedation
Number of subjects: 0
Study 31196776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist's educational intervention
Number of subjects: 450
Study 28807019 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal syphilis screening and treatment intervention (details on dosage and duration not available)
Number of subjects: 112
Study 24700992 — intervention group
Group type: COMPARATOR
Intervention: Bypassers (women who bypassed local primary care clinics for childbirth)
Number of subjects: 3019
Study 24700992 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who delivered in a health facility (non-bypassers)
Number of subjects: 3019
Study 24700992 — intervention group
Group type: COMPARATOR
Intervention: Women who perceived poor quality at clinics
Number of subjects: 3019
Study 24700992 — intervention group
Group type: COMPARATOR
Intervention: Women who delivered at clinics that recently underwent renovations
Number of subjects: 3019
Study 24700992 — intervention group
Group type: COMPARATOR
Intervention: Women who delivered at clinics performing ≥ 4 obstetric signal functions
Number of subjects: 3019
Study 24700992 — intervention group
Group type: COMPARATOR
Intervention: Primiparous women (first-time mothers)
Number of subjects: 3019
Study 22381427 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) treatment
Number of subjects: 884
Study 20473071 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical health recommendations and nonspecific interactions with study patients
Number of subjects: 0
Study 20473071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive, behavioral, and emotionally supportive interventions
Number of subjects: 0
Study 20473071 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator's personal experiences and siding with the patient on interpersonal conflicts
Number of subjects: 0
Study 20473071 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent with patients at midstudy visits
Number of subjects: 0
Study 17667193 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program (group 1)
Number of subjects: 50
Study 17667193 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 50
Study 16181595 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Imagery (MI) and Kinesiology (KG)
Number of subjects: 44
Study 16181595 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology (KG) alone
Number of subjects: 44
Study 16181595 — intervention group
Group type: COMPARATOR
Intervention: Control (Advandec Trauma Life Support - ATLS)
Number of subjects: 44
Study 11874395 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal after 1 h
Number of subjects: 12
Study 11874395 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric lavage followed by activated charcoal after 1 h
Number of subjects: 12
Study 11874395 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal after 2 h
Number of subjects: 12
Study 11874395 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 12
Study 10402370 — intervention group
Group type: EXPERIMENTAL
Intervention: Puregon(R)Pen
Number of subjects: 22
Study 10402370 — intervention group
Group type: COMPARATOR
Intervention: Syringe
Number of subjects: 22
Study 10402370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 22
Study 10402370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 22
Study 7992934 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.30 mg)
Number of subjects: 0
Study 7992934 — intervention group
Group type: COMPARATOR
Intervention: Morphine (10 mg)
Number of subjects: 0
Study 2675669 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion formulation of etomidate
Number of subjects: 16
Study 2675669 — intervention group
Group type: COMPARATOR
Intervention: Propylene glycol formulation of etomidate (Hypnomidate)
Number of subjects: 16
Study 1253812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose administered simultaneously with ethanol
Number of subjects: 109
Study 1253812 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose administered simultaneously with ethanol
Number of subjects: 109
Study 1253812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose administered 12 hours later during the hangover period
Number of subjects: 109
Study 1253812 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose administered 12 hours later during the hangover period
Number of subjects: 109
Study 1253812 — intervention group
Group type: COMPARATOR
Intervention: Ethanol only (control group)
Number of subjects: 109
Study 1253812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 109
Study 1253812 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 109
Study 1253812 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of fructose and glucose
Number of subjects: 109
Study 31786715 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanic prestimulation (50 Hz for 5 s)
Number of subjects: 80
Study 31786715 — intervention group
Group type: COMPARATOR
Intervention: No tetanic prestimulation (control)
Number of subjects: 80
Study 31533195 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone supplementation
Number of subjects: 151
Study 29042490 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 30
Study 29042490 — intervention group
Group type: COMPARATOR
Intervention: Sham ischemia-reperfusion cycles
Number of subjects: 30
Study 26252642 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk post exercise
Number of subjects: 54
Study 26252642 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate beverage (CONT)
Number of subjects: 54
Study 26252642 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study 22986418 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sevoflurane in N(2)O 4 litre min(‐1) and O(2) 2 litre min(‐1)
Number of subjects: 80
Study 22986418 — intervention group
Group type: COMPARATOR
Intervention: 8% sevoflurane in O(2) 6 litre min(‐1)
Number of subjects: 80
Study 22986418 — intervention group
Group type: EXPERIMENTAL
Intervention: N(2)O
Number of subjects: 80
Study 22071711 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm olein
Number of subjects: 32
Study 22071711 — intervention group
Group type: EXPERIMENTAL
Intervention: Lard
Number of subjects: 32
Study 22071711 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 32
Study 19893201 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) treatment
Number of subjects: 0
Study 17111195 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis with ultra-high dose streptokinase (n = 8)
Number of subjects: 15
Study 17111195 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis with alteplase (tPA) (n = 7)
Number of subjects: 15
Study 17111195 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (combined results)
Number of subjects: 15
Study 15317270 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietaria pollen vaccine
Number of subjects: 30
Study 15317270 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo injections
Number of subjects: 30
Study 10668686 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed conjugated equine estrogens (1.25 mg/day) for 16 weeks
Number of subjects: 42
Study 10668686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 9061102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (20 mg or 40 mg oral controlled-release tablet)
Number of subjects: 98
Study 8227788 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 20
Study 8227788 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 20
Study 3021324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (600 mg intramuscularly in a single administration, followed by 200 mg 3 times per day from days 2-21, then 100 mg and 50 mg 3 times per day on days 22-25 and 26-29, respectively)
Number of subjects: 410
Study 3021324 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group of 10 heroin addicts)
Number of subjects: 410
Study 30021580 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) at 60 seconds
Number of subjects: 113
Study 30021580 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (ECC) immediately after birth
Number of subjects: 113
Study 30021580 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 113
Study 30021580 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) and Early cord clamping (ECC)
Number of subjects: 113
Study 27540883 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 949
Study 27540883 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 949
Study 27540883 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 949
Study 24434302 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous reinfusion by cell saver or DRAIN
Number of subjects: 1759
Study 24434302 — intervention group
Group type: COMPARATOR
Intervention: No blood salvage device (Control)
Number of subjects: 1759
Study 22037130 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 37
Study 22037130 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 37
Study 22037130 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 37
Study 20188175 — intervention group
Group type: EXPERIMENTAL
Intervention: M01ZH09 (typhoid vaccine)
Number of subjects: 187
Study 20188175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 17942447 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention for on-site, in-charge reproductive health supervisors
Number of subjects: 60
Study 16330302 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori test-and-treat strategy
Number of subjects: 223
Study 16330302 — intervention group
Group type: COMPARATOR
Intervention: Prompt endoscopy
Number of subjects: 223
Study 15071265 — intervention group
Group type: EXPERIMENTAL
Intervention: AAIR pacing
Number of subjects: 0
Study 15071265 — intervention group
Group type: COMPARATOR
Intervention: VVI(R) pacing
Number of subjects: 0
Study 15071265 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing
Number of subjects: 0
Study 10222388 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard infant formula (HP group)
Number of subjects: 0
Study 10222388 — intervention group
Group type: COMPARATOR
Intervention: Recommended dietary regimen (LP group)
Number of subjects: 0
Study 8902444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose complex (ISC)
Number of subjects: 111
Study 8902444 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (control)
Number of subjects: 111
Study 1725547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary diltiazem (500 micrograms i.c. bolus)
Number of subjects: 25
Study 6357036 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical povidone‐iodine spray in addition to a single dose of intravenous metronidazole
Number of subjects: 200
Study 6357036 — intervention group
Group type: COMPARATOR
Intervention: Single dose of intravenous metronidazole
Number of subjects: 200
Study 31440235 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 31440235 — intervention group
Group type: COMPARATOR
Intervention: Standard Corticosteroid (CS) treatment
Number of subjects: 0
Study 28682676 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) (635 nm)
Number of subjects: 24
Study 28682676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27531014 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of physical activity (5-7 times per week)
Number of subjects: 1569
Study 27531014 — intervention group
Group type: COMPARATOR
Intervention: Low level of physical activity (1-2 times per week)
Number of subjects: 1569
Study 25902655 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 5‐10 mg/day + Indapamide retard 1.5 mg/day (P+I)
Number of subjects: 40
Study 25902655 — intervention group
Group type: COMPARATOR
Intervention: Perindopril 5‐10 mg/day + Hydrochlorothiazide 25 mg/day (P+HT)
Number of subjects: 40
Study 21536813 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-notification letter
Number of subjects: 59953
Study 21536813 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-notification letter + information booklet
Number of subjects: 59953
Study 21536813 — intervention group
Group type: COMPARATOR
Intervention: Usual invitation
Number of subjects: 59953
Study 19675482 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression tights (CG)
Number of subjects: 11
Study 19675482 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (CON)
Number of subjects: 11
Study 18705444 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) with spontaneous ventilation
Number of subjects: 100
Study 18705444 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT) with intermittent positive pressure ventilation (IPPV)
Number of subjects: 100
Study 15510982 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (5000 U/day subcutaneously three times a week) until three weeks after chemotherapy completion in Groups 1, 2A, and 3A
Number of subjects: 77
Study 15510982 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO for 12 weeks in Groups 2B and 3B
Number of subjects: 77
Study 15510982 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO usage strategies
Number of subjects: 77
Study 11304102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 9287
Study 11304102 — intervention group
Group type: COMPARATOR
Intervention: No Ramipril (Control)
Number of subjects: 9287
Study 11304102 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal insufficiency
Number of subjects: 9287
Study 9187888 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy with a combination of oestrogen and progesterone
Number of subjects: 0
Study 9187888 — intervention group
Group type: COMPARATOR
Intervention: Traditional management (surgical resection and endoscopic fulguration)
Number of subjects: 0
Study 7945738 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg cocaine
Number of subjects: 14
Study 7945738 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg cocaine
Number of subjects: 14
Study 7945738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3605793 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol nebulized by facial mask
Number of subjects: 150
Study 3605793 — intervention group
Group type: COMPARATOR
Intervention: epinephrine by subcutaneous injection
Number of subjects: 150
Study 29655928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting callisthenic balance (SCB)
Number of subjects: 0
Study 29655928 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RET)
Number of subjects: 0
Study 27621249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided stellate ganglion blockade (SGB)
Number of subjects: 36
Study 27621249 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 36
Study 24841321 — intervention group
Group type: EXPERIMENTAL
Intervention: Avonex
Number of subjects: 90
Study 24841321 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebif
Number of subjects: 90
Study 24841321 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaferon
Number of subjects: 90
Study 22925609 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT) plus active exercises (AE)
Number of subjects: 42
Study 22925609 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (ST) plus active exercises (AE)
Number of subjects: 42
Study 20456826 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate cream formulations (0.05%)
Number of subjects: 0
Study 18667647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethics consultation
Number of subjects: 0
Study 18667647 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trials
Number of subjects: 0